Clinical Trials Logo
  1. Home
  2. HCV
  3. NCT00823745

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

HCV Clinical Trial

Official title:
A Phase 1 Study To Evaluate The Metabolism And Excretion Of [14C] PF-00868554 In Healthy Adult Male Subjects

Clinical Trial Summary

This is a phase 1 study to assess the routes of elimination of a single oral dose of [14C] PF-00868554 and to characterize the metabolic profile following single dose administration.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00823745
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 1
Start date January 2009
Completion date February 2009
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05942937 - National Prisons Hepatitis Education Project: Research Evaluation N/A
Completed NCT02604017 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection Phase 3
Completed NCT01221298 - A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) Phase 2
Recruiting NCT05794646 - Community Intervention to Eliminate HCV Among People Who Use Drugs. N/A
Completed NCT04971330 - Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol
Completed NCT02247401 - Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt Phase 3
Completed NCT02833298 - Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening N/A
Active, not recruiting NCT03981445 - Integrated HIV Prevention and HCV Care for PWID N/A
Completed NCT02452814 - Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection N/A
Recruiting NCT05904470 - A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Phase 2
Not yet recruiting NCT06316739 - The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City N/A
Completed NCT02116543 - TD-6450 MAD Study in HCV Infected Subjects Phase 1
Recruiting NCT05454579 - The South-East Asian Transgender Health Cohort
Active, not recruiting NCT03221309 - Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
Completed NCT03801707 - Utilization of Hepatitis C Positive Kidneys in Negative Recipients Phase 2/Phase 3
Not yet recruiting NCT03820102 - Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs
Completed NCT01074008 - A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 Phase 2
Completed NCT05616598 - Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters Phase 2/Phase 3
Recruiting NCT05854511 - Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children Phase 3
Completed NCT03069001 - Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV Phase 4